

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Lenvima (lenvatinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Lenvima (lenvatinib) 4mg daily dose pack	1 pack per 30 days (30 capsules)
Lenvima (lenvatinib) 8mg daily dose pack	1 pack per 30 days (60 capsules)
Lenvima (lenvatinib) 10mg daily dose pack	1 pack per 30 days (30 capsules)
Lenvima (lenvatinib) 12mg daily dose pack	1 pack per 30 days (90 capsules)
Lenvima (lenvatinib) 14mg daily dose pack	1 pack per 30 days (60 capsules)
Lenvima (lenvatinib) 18mg daily dose pack	1 pack per 30 days (90 capsules)
Lenvima (lenvatinib) 20mg daily dose pack	1 pack per 30 days (60 capsules)
Lenvima (lenvatinib) 24mg daily dose pack	1 pack per 30 days (90 capsules)

APPROVAL CRITERIA

Requests for Lenvima (lenvatinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC);

OR

- II. Individual has a diagnosis of thyroid carcinoma, including medullary, papillary, follicular, or Hürthle cell carcinomas (NCCN 2A);

OR

- III. Individual has a diagnosis of renal cell carcinoma; **AND**
- IV. Individual is using in combination with everolimus; **AND**
- V. Individual has received prior anti-angiogenic therapy, such as but not limited to Avastin (bevacizumab) with interferon alfa; Sutent (sunitinib); or Votrient (pazopanib);

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

OR

VI. Individual has a diagnosis of unresectable hepatocellular carcinoma (HCC) (label, NCCN 2A).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 8/2018

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.